Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations
You may also be interested in...
Decks Cleared For Mylan-Agila Deal But More Headwinds In Sight On Foreign Buyouts
A six-month drama over the $1.6 billion Mylan-Agila deal has ended as India’s prime minister intervened amid inter-departmental conflicts. However buyouts will not be any easier for multinational companies as new rules are being worked out for tighter controls.
Decks Cleared For Mylan-Agila Deal But More Headwinds In Sight On Foreign Buyouts
A six-month drama over the $1.6 billion Mylan-Agila deal has ended as India’s prime minister intervened amid inter-departmental conflicts. However buyouts will not be any easier for multinational companies as new rules are being worked out for tighter controls.
India’s Ministries Bury Hatchet On Buyout Norms; Action Shifts To Prime Minister’s Office
Proposed policy guidelines will seek to balance foreign investments and public health needs.